Browse
Submit Data
Databases
API
Help
Login

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Marked Disparity of MicroRNA Modulation by cGMP-selective PDE5 versus PDE9 Inhibitors in Heart Disease

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE112056 | GEO | 2018/08/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

primary

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.

Project description:MicroRNAs (miRs) posttranscriptionally regulate mRNA and its translation into protein, and are considered master controllers of genes modulating normal physiology and disease. There is growing interest in how miRs change with drug treatment, and leveraging this for precision guided therapy. Here we contrast 2 closely related therapies, inhibitors of phosphodiesterase type 5 or type 9 (PDE5-I, PDE9-I), given to mice subjected to sustained cardiac pressure overload (PO). Both inhibitors augment cyclic guanosine monophosphate (cGMP) to activate protein kinase G, with PDE5-I regulating nitric oxide (NO) and PDE9-I natriuretic peptide-dependent signaling. While both produced strong phenotypic improvement of PO pathobiology, they surprisingly showed binary differences in miR profiles; PDE5-I broadly reduces more than 120 miRs, including nearly half those increased by PO, whereas PDE9-I has minimal impact on any miR (P < 0.0001). The disparity evolves after pre-miR processing and is organ specific. Lastly, even enhancing NO-coupled cGMP by different methods leads to altered miR regulation. Thus, seemingly similar therapeutic interventions can be barcoded by profound differences in miR signatures, and reversing disease-associated miR changes is not required for therapy success.

| S-EPMC6129132 | BioStudies

Marked Disparity of MicroRNA Modulation by cGMP-selective PDE5 versus PDE9 Inhibitors in Heart Disease

Project description:Marked Disparity of MicroRNA Modulation by cGMP-selective PDE5 versus PDE9 Inhibitors in Heart Disease

| PRJNA439190 | ENA

microRNA and gene expression profile in ischemia reperfusion injury in heart transplantation

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

| E-GEOD-50886 | BioStudies

In vivo activation of a conserved microRNA program induces robust mammalian heart regeneration

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

| E-GEOD-62389 | BioStudies

microRNA Induction of Fatal Differentiation Programs is a Context-selective Vulnerability in Ovarian Cancer Cells

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

| E-GEOD-67330 | BioStudies

Covalent targeting of remote cysteine residues for the development of selective CDK12/13 inhibitors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

| E-GEOD-72031 | BioStudies

Inhibitors selective for mycobacterial versus human proteasomes.

Project description:Many anti-infectives inhibit the synthesis of bacterial proteins, but none selectively inhibits their degradation. Most anti-infectives kill replicating pathogens, but few preferentially kill pathogens that have been forced into a non-replicating state by conditions in the host. To explore these alternative approaches we sought selective inhibitors of the proteasome of Mycobacterium tuberculosis. Given that the proteasome structure is extensively conserved, it is not surprising that inhibitors of all chemical classes tested have blocked both eukaryotic and prokaryotic proteasomes, and no inhibitor has proved substantially more potent on proteasomes of pathogens than of their hosts. Here we show that certain oxathiazol-2-one compounds kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the M. tuberculosis proteasome by cyclocarbonylating its active site threonine. Major conformational changes protect the inhibitor-enzyme intermediate from hydrolysis, allowing formation of an oxazolidin-2-one and preventing regeneration of active protease. Residues outside the active site whose hydrogen bonds stabilize the critical loop before and after it moves are extensively non-conserved. This may account for the ability of oxathiazol-2-one compounds to inhibit the mycobacterial proteasome potently and irreversibly while largely sparing the human homologue.

| S-EPMC3172082 | BioStudies

Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.

Project description:The members of the Aurora kinase family play critical roles in the regulation of the cell cycle and mitotic spindle assembly and have been intensively investigated as potential targets for a new class of anticancer drugs. We describe a new highly potent and selective class of Aurora kinase inhibitors discovered using a phenotypic cellular screen. Optimized inhibitors display many of the hallmarks of Aurora inhibition including endoreduplication, polyploidy, and loss of cell viability in cancer cells. Structure-activity relationships with respect to kinome-wide selectivity and guided by an Aurora B co-crystal structure resulted in the identification of key selectivity determinants and discovery of a subseries with selectivity toward Aurora A. A direct comparison of biochemical and cellular profiles with respect to published Aurora inhibitors including VX-680, AZD1152, MLN8054, and a pyrimidine-based compound from Genentech demonstrates that compounds 1 and 3 will become valuable additional pharmacological probes of Aurora-dependent functions.

| S-EPMC3262907 | BioStudies

Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells.

Project description:The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. Guided by X-ray crystallography and structure-based optimization, we report a novel subseries of C-3-substituted 6-ethynyl-1H-indole derivatives that display high potential and specificity towards group II PAKs. Among these inhibitors, compound 55 exhibited excellent inhibitory activity and kinase selectivity, displayed superior anti-migratory and anti-invasive properties against the lung cancer cell line A549 and the melanoma cell line B16. Compound 55 exhibited potent in vivo antitumor metastatic efficacy, with over 80% and 90% inhibition of lung metastasis in A549 or B16-BL6 lung metastasis models, respectively. Further mechanistic studies demonstrated that compound 55 mitigated TGF-β1-induced epithelial-mesenchymal transition (EMT).

| S-EPMC9214071 | BioStudies

Comparison of microRNA Profiling Platforms

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

| E-GEOD-51508 | BioStudies